Literature DB >> 15271309

Time trends in pathologic features of radical prostatectomy--impact of family history.

Jeffrey B Marotte1, Michelle K Ferrari, John E McNeal, James D Brooks, Joseph C Presti.   

Abstract

We investigated whether the clinical or pathological features of patients with a family history of prostate cancer treated by radical prostatectomy differ from patients without a family history. A retrospective analysis of patients treated by radical prostatectomy between 1989 through 2000 was performed. The clinical and pathologic features of patients with a family history (defined as at least one first-degree relative with prostate cancer, N = 103) were compared with those with no family history (N = 456). In addition, the patients were stratified into two groups, those treated from 1989 through 1992 and those treated after 1992. In the entire cohort from 1989 through 2000, patients with a family history had a greater proportion of well-differentiated tumors than the NFH group (26.2% vs. 17.8%; P = 0.05). From 1989 to 1992 there was no statistical difference between patients with a family history (FH) and those without a family history (NFH) with respect to age, prostate specific antigen (PSA), PSA density, clinical or pathologic stage, Gleason grade, or total tumor volume. However, after 1992 the FH group tended to be younger than the NFH group (61.1 vs. 63.4; P = 0.02) and have a lower PSA (6.8 vs. 7.9; P = 0.01) at the time of diagnosis. We believe these differences are predominantly driven by more aggressive screening in patients with a family history of prostate cancer rather than any true genetic differences. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15271309     DOI: 10.1016/j.urolonc.2004.04.003

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  3 in total

1.  [Association of a positive family history with histopathology and clinical course in early-onset prostate cancer].

Authors:  K Herkommer; T Paiss; M Merz; J E Gschwend; M Kron
Journal:  Urologe A       Date:  2006-12       Impact factor: 0.639

2.  [Familial prostate cancer research: meaningfulness of hereditary criteria in view of demographic change].

Authors:  K Herkommer; M Heimpel; J E Gschwend
Journal:  Urologe A       Date:  2014-12       Impact factor: 0.639

3.  The feasibility and results of a population-based approach to evaluating prostate-specific antigen screening for prostate cancer in men with a raised familial risk.

Authors:  J Melia; D Dearnaley; S Moss; L Johns; P Coulson; C Moynihan; J Sweetman; M C Parkinson; R Eeles; M Watson
Journal:  Br J Cancer       Date:  2006-02-27       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.